EID Parry (India) Ltd — FY 2023 Annual Report Analysis

Annual Report Analysis (Consolidated)

Source: CRORES. All figures Crores. Pipeline: v5-Gemini — W1a → W3 → W1b+W2+W2F (parallel, notes-injected) → Merge.

Investor Snapshot

#	Analytical Point	Sentiment
1	**The business is executing a strategic pivot toward high-margin Bio-energy and FMCG, with Ethanol now contributing 22% of standalone revenue to reduce cyclical sugar exposure.**	□
2	**Consolidated revenue surged 49.84% to □35,244 Cr, driven by the fertilizer subsidiary and aggressive scaling of the distillery segment.**	□
3	***Operating margins face pressure from a 2,022 Cr working capital drain, primarily due to a 39.4% spike in finished goods inventory and subsidy delays.***	□
4	**Reported PAT reached □1,828 Cr, supported by strong sugar recovery rates of 11.89% in key regions and a shift toward higher-margin ethanol juice diversion.**	□
5	***Total debt rose to 1,618 Cr with a concerning 90.7% concentration in short-term borrowings, causing interest costs to double to 298 Cr.***	□
6	***Cash Flow from Operations (CFO) collapsed to 359 Cr, representing a severe red-flag conversion rate of only 20% of PAT.***	□
7	***Aggressive capex of 839 Cr (2.34x CFO) has pushed Free Cash Flow into negative territory at - 370 Cr.***	□
8	***Earnings quality is compromised by aggressive accounting, including 60-year asset lives for buildings and a massive disconnect between accrual profits and cash realization.***	□
9	Governance remains a core strength with 0% promoter pledging, 50% board independence, and a clean 10/10 governance scorecard.	□
10	***Significant execution and valuation risks persist due to the 254 Cr loss and 106 Cr impairment at the PSRIPL refinery subsidiary.***	□
11	The outlook depends on the successful commissioning of the 582 KLPD distillery capacity by April 2024 and the liquidation of the □3,007 Cr inventory pile.	□
12	Investment View: WATCH; maintain a cautious stance until the CFO/PAT ratio exceeds 0.70x and inventory levels normalize below □2,200 Cr.	□

1. BUSINESS OVERVIEW

- **Strategic Pivot:** EID Parry is transitioning from a cyclical sugar commodity player to a "Bio-energy, Food, and Nutrition" company to de-link valuation from industry volatility.
- **Business Verticals:** The company operates through four segments: Sugar (Institutional & Retail), Distillery (Ethanol & ENA), Co-generation (Power), and Nutraceuticals (Micro-algae like Spirulina).
- **Revenue Drivers:** Ethanol is the primary growth engine, now contributing ~22% of standalone revenues. Institutional sugar sales (35% of sugar revenue) provide a buffer against retail price volatility.

- **Cost Drivers:** Sugarcane accounts for >90% of sugar production costs. Mitigation strategies include improving recovery rates (11.89% in Karnataka) and closing under-utilized factories in Tamil Nadu.
- **Expansion Plans:** Distillery capacity is expanding from 297 KLPD to 582 KLPD by April 2024, including a 120 KLPD multi-feed distillery at Sankili and 165 KLPD across Haliyal and Nellikuppam.
- **Asset-Light Strategy:** Management plans to move into non-sweetener food products using an asset-light model, leveraging the 'Parry's' brand while outsourcing manufacturing.
- **Acquisitions & Subsidiaries:** Coromandel International (CIL) remains the "crown jewel" providing financial flexibility. Conversely, the refinery subsidiary (PSRIPL) is a pain point, incurring a ₹254 Cr loss and a ₹106 Cr impairment.
- **Geographical Presence:** Shifting assets from Tamil Nadu to Karnataka to capture higher cane availability and superior recovery yields.

2. MANAGEMENT COMMENTARY & OUTLOOK

- Management has adopted a "conscious sacrifice" strategy, diverting sugarcane juice away from sugar production to ethanol (100,698 MT sacrificed in FY23 vs 59,447 MT in FY22) to prioritize margins over volume.
- The distillery segment is viewed as a "cash-accretive" engine that structurally shortens the working capital cycle from 14 months (sugar) to 3-4 weeks (ethanol).
- Management is highly optimistic about the Government of India's 20% Ethanol Blending Program (EBP) target by 2025.
- The company is aggressively pushing Branded Sugar, aiming to increase retail reach from 70,000 outlets to 500,000 in the medium term.
- Sugar is being repositioned as a "health and hygiene" product with the launch of Low GI (Glycemic Index) sugar and "Sweet Care" for urban demographics.
- Management remains wary of the "tightly controlled" regulatory environment (FRP pricing, export quotas) and is diversifying into Nutraceuticals and Branded Foods to gain pricing power.
- Despite temporary slowdowns in US/EU markets, management is doubling down on science-based validation for the Nutraceuticals business to maintain a premium position.
- The successful commissioning of the 120 KLPD distillery at Sankili in Q4 FY23 demonstrates strong project execution capability.
- Management Tone: The management tone is **Pragmatically Aggressive**. There is a clear admission of the unviability of commodity sugar in certain geographies, balanced by a high-conviction bet on Bio-energy and Branded Foods. While transparent regarding the failures in the refinery business (PSRIPL), they remain highly optimistic about "reimagining" the brand as a "Value-Added Agri-Science" entity.

3. FINANCIAL ANALYSIS

3.1 Financial Statements

Source: Screener.in — all monetary values in Crores. Use these numbers directly.

P&L Statement (Crores)

Line Item	Mar 2023	Mar 2022
Sales -	35,244.00	23,521.00
Sales Growth %	49.84	26.76
Expenses -	32,088.00	21,146.00
Material Cost % -	79.00	75.00
Raw material cost	28,882.00	17,769.00
Change in inventory	-971.00	-148.00
Manufacturing Cost %	3.00	4.00
Employee Cost %	2.00	3.00
Other Cost %	6.00	8.00
Operating Profit	3,156.00	2,375.00
OPM %	9.00	10.00
Other Income -	83.00	240.00
Exceptional items	56.00	-14.00
Other income normal	28.00	254.00
Interest	298.00	152.00
Depreciation	376.00	334.00
Profit before tax	2,564.00	2,129.00
Tax %	29.00	26.00
Net Profit -	1,828.00	1,574.00
Minority share	-880.00	-667.00
Exceptional items AT	40.00	-10.00
Profit excl Excep	1,788.00	1,584.00
Profit for PE	927.00	913.00
Profit for EPS	947.00	907.00
Profit Growth %	2.00	91.00
EPS in Rs	53.37	51.12
Dividend Payout %	18.00	22.00

Balance Sheet (₹ Crores)

Line Item	Mar 2023	Mar 2022
Equity Capital	18.00	18.00
Reserves	6,067.00	5,308.00
Borrowings -	1,618.00	1,259.00
Long term Borrowings	111.00	79.00
Short term Borrowings	1,080.00	743.00
Lease Liabilities	427.00	437.00
Other Borrowings	0.00	0.00
Other Liabilities -	11,076.00	9,358.00
Non controlling int	3,454.00	2,774.00
Trade Payables	6,456.00	5,497.00
Advance from Customers	140.00	231.00
Other liability items	1,025.00	855.00
Total Liabilities	18,778.00	15,943.00
Fixed Assets -	3,889.00	3,763.00
Land	615.00	610.00
Building	1,246.00	1,124.00
Plant Machinery	4,730.00	4,428.00
Furniture n fittings	182.00	153.00
Railway sidings	0.00	0.00
Vehicles	60.00	46.00
Intangible Assets	66.00	62.00
Other fixed assets	142.00	126.00
Gross Block	7,041.00	6,548.00
Accumulated Depreciation	3,152.00	2,785.00
CWIP	486.00	160.00
Investments	609.00	563.00
Other Assets -	13,794.00	11,456.00
Inventories	6,195.00	5,363.00
Trade receivables	812.00	573.00
Cash Equivalents	1,466.00	1,839.00
Loans n Advances	714.00	1,533.00
Other asset items	4,607.00	2,147.00
Total Assets	18,778.00	15,943.00

Cash Flow Statement (□Crores)

Line Item	Mar 2023	Mar 2022
Cash from Operating Activity -	359.00	2,278.00
Profit from operations	3,078.00	2,573.00
Receivables	-244.00	279.00
Inventory	-823.00	-1,289.00
Payables	1,472.00	1,065.00
Other WC items	-2,427.00	161.00
Working capital changes	-2,022.00	217.00
Direct taxes	-698.00	-511.00
Cash from Investing Activity -	487.00	-1,732.00
Fixed assets purchased	-839.00	-449.00
Fixed assets sold	111.00	16.00
Investments purchased	-55.00	0.00
Investments sold	6.00	29.00
Investment income	0.00	0.00
Interest received	145.00	107.00
Dividends received	1.00	1.00
Invest in subsidiaries	0.00	0.00
Investment in group cos	-157.00	-19.00
Redemp n Canc of Shares	0.00	0.00
Inter corporate deposits	242.00	-418.00
Other investing items	1,032.00	-999.00
Cash from Financing Activity -	-184.00	-499.00
Proceeds from shares	23.00	12.00
Proceeds from debentures	0.00	0.00
Proceeds from borrowings	383.00	245.00
Repayment of borrowings	-24.00	-226.00
Interest paid fin	-251.00	-110.00
Dividends paid	-246.00	-349.00
Financial liabilities	-70.00	-72.00
Other financing items	0.00	0.00
Net Cash Flow	661.00	47.00
Free Cash Flow	-370.00	1,845.00
CFO/OP	33.00	117.00

Key Ratios (₹Crores)

Line Item	Mar 2023	Mar 2022
Debtor Days	8.00	9.00
Inventory Days	81.00	111.00
Days Payable	84.00	114.00
Cash Conversion Cycle	5.00	6.00
Working Capital Days	27.00	29.00
ROCE %	27.00	26.00

3.2 Financial Analysis Summary

- **Revenue** surged 49.84% to **₹35,244.00 Cr**, with 84.5% of total income (**₹29,799.03 Cr**) contributed by the subsidiary Coromandel International Ltd, though top-line quality is subject to management judgment via the "most likely method" for rebates and Nutrient Based Subsidy (NBS) estimations.
- **Operating Profit** grew to **₹3,156.00 Cr**, but **OPM %** diluted to **8.95%** as **Material Cost %** rose to **79.00%**, driven by a 58.4% spike in inventory consumption costs to **₹27,911.38 Cr** which was only partially offset by a **₹19.01 Cr** reversal of previous **Inventory** write-downs.
- **Net Profit** reached **₹1,828.00 Cr**, yet earnings quality is impacted by a **Depreciation** policy that uses technical evaluations to stretch the useful lives of **Fixed Assets** up to 60 years, potentially inflating **PAT** relative to standard accounting lives.
- **Cash from Operating Activity** collapsed to **₹359.00 Cr** from **₹2,278.00 Cr**, resulting in a poor **CFO/PAT** ratio of **0.20**, as **Working Capital** changes drained **₹2,022.00 Cr** due to a 39.4% buildup in finished goods **Inventory** to **₹3,007.82 Cr** and **₹825 Cr** locked in government balances and advances.
- **Trade Receivables** grew 41.5% to **₹811.95 Cr**, outpacing the 15.5% growth in total **Inventory**, signaling potential credit loosening or delays in government subsidy realizations, which directly contributed to the **-₹244.00 Cr** drain in the **Cash Flow Statement**.
- **Total Debt** increased to **₹1,618.00 Cr**, with **Short term Borrowings** comprising 90.7% of the total (**₹1,080.20 Cr**), leading to a doubling of **Interest** costs to **₹298.00 Cr** and reducing the **Interest Coverage** ratio from **15.01** to **9.60**.
- **Capex** of **₹839.00 Cr** was 2.34x the **CFO**, forcing the company into a negative **Free Cash Flow** of **-₹370.00 Cr**, while **CWIP** ballooned 3.5x to **₹486.00 Cr**, indicating high execution risk for ongoing projects.
- **ROCE %** improved slightly to **27.00%**, but the group faces asset quality risks at the PSRIPL subsidiary, where management avoided impairment of **Fixed Assets** despite two years of losses and the functional currency being USD, which introduces translation volatility.
- **Investments** of **₹609.00 Cr** include strategic holdings like TIFERT, where shares are pledged to secure associate debt, and others like APGPCL which have been written down to Nil value, indicating historical capital allocation leakage.
- **Net Worth** grew via **Reserves** to **₹6,067.00 Cr**, but the group holds **₹1,640.00 Cr** in inter-corporate deposits with HDFC Ltd instead of utilizing this cash to pay down high-interest **Short term Borrowings** or fund the massive **Working Capital** requirements.
- **Other Assets** include **₹479.98 Cr** in "Balance with Government Authorities" and **₹345.96 Cr** in "Advance Recoverable in Kind," representing nearly **₹825 Cr** of liquidity locked in non-cash forms (GST/Subsidies). **Other Liabilities** are impacted by a new **₹97.63 Cr** provision for demurrages, suggesting significant logistical inefficiencies. **Other Expenses** were pressured by a **₹157.46 Cr** mark-to-market loss on commodity futures.

- The dominant financial theme of the year is **aggressive top-line scaling and capital expenditure funded by debt and working capital depletion, leading to a severe disconnect between accounting profits and cash generation.**

3.3 Contingent Liabilities & Commitments

- **Share Pledge:** The group has pledged 33.75 lakh shares of Tunisian Indian Fertilisers S.A. (TIFERT) to secure the associate's lenders.
- **Capital Commitments:** Significant ongoing commitments for PPE (Note 51 referenced), evidenced by the **□486 Cr** CWIP balance.
- **Litigation:** Provisions are only made when obligations are "probable"; however, specific quantified litigation values were not disclosed in the provided report snippets.

3.9 Earnings Quality & Forensic Checks

#	Check	Impact	Status	Evidence	Notes Detail
1	PAT vs CFO trend	Profit ↓ — earnings overstate cash; □359 Cr CFO vs □1,828 Cr PAT indicates poor cash conversion.	□	CFO □359 Cr (FY23) vs □2,278 Cr (FY22); PAT □1,828 Cr.	CFO/OP ratio plummeted from 117% to 33% due to massive working capital blockage.
2	Receivables & channel-stuffing signal	Revenue ↑↓ — channel stuffing risk; combined receivables and inventory rose □1,071 Cr vs sales growth.	□	Receivables +41.5% (□812 Cr); Inventory +15.5% (□6,195 Cr); Sales +49.8%.	Note 9: Receivables growth outpaced inventory growth, suggesting potential loosening of credit terms to drive sales.
3	Revenue timing	Revenue ↑ — aggressive recognition; subsidy income recognized on estimates before government notification finalization.	□	Advances from customers fell to □140 Cr from □231 Cr.	Note 1.6(ii): Coromandel revenue relies on management estimates for NBS rates when official notifications are pending.
4	Revenue from related parties %	Neutral — low direct RPT revenue; receivables from director-related companies are negligible at □0.11 Cr.	□	RPT Receivables: □0.11 Cr (FY23) vs □0.24 Cr (FY22).	Note 18.2: Promoter holding remains stable at 38.34%; direct related party sales are not a material concern.
5	Inventory vs revenue growth	Profit ↓ — margin pressure; finished goods inventory spiked 39.4% indicating potential unsold stock buildup.	□	Inventory □6,195 Cr; Finished Goods □3,007 Cr (up from □2,157 Cr).	Note 13: Massive buildup in finished goods carries risk of obsolescence or price correction in sugar/fertilizer.
6	Inventory valuation method change	Profit ↑↓ — inconsistency risk; different subsidiaries use different valuation methods (Specific ID vs Weighted Avg).	□	PSRIPL uses specific identification; Coromandel changed raw material valuation method.	Note 1.20: Inconsistent valuation methods across the group complicate consolidated margin and earnings quality analysis.
7	Exceptional items in operating profit	Profit ↑ — non-recurring boost; □56 Cr exceptional gain included in PBT calculation for FY23.	□	Exceptional items: □56 Cr (FY23) vs -□14 Cr (FY22).	P&L: Exceptional items contributed to the 2% growth in Profit for EPS despite operational cash flow stress.
8	Depreciation rate vs useful life policy	Profit ↑ — lower expenses; useful lives extended up to 60 years for buildings, reducing annual charges.	□	Depreciation □376 Cr on Gross Block of □7,041 Cr (~5.3%).	Note 1.16: Depreciation based on technical evaluations rather than Schedule II, allowing for potentially stretched asset lives.
9	Provision reversals boosting PAT	Profit ↑ — non-cash gain; □19.01 Cr inventory write-down reversal directly improved the bottom line.	□	Reversal of write-downs: □19.01 Cr (FY23) vs □10.64 Cr (FY22).	Note 13: Frequent reversals of inventory write-downs can be used to smooth earnings during high-cost periods.
10	Tax rate consistency	Profit ↓ — higher tax outflow; effective tax rate rose to 29% from 26% YoY.	□	Tax %: 29.00; Direct Taxes Paid: □698 Cr vs P&L Tax Provision.	P&L: Tax rate is consistent with statutory norms, though cash tax paid is significantly higher than previous year.
11	CWIP age and stalling projects	Profit ↑ — interest capitalization; CWIP increased 3x, delaying depreciation and potentially masking project delays.	□	CWIP: □486 Cr (FY23) vs □160 Cr (FY22).	Forensic Note: 3.5x increase in CWIP suggests large projects are not yet commissioned, delaying returns on capital.
12			□		

#	Check	Impact	Status	Evidence	Notes Detail
	Deferred tax asset recognition adequacy	Profit ↑ — subjective valuation; management avoided impairment on loss-making PSRIPL using "value in use" projections.		PSRIPL carrying value of PPE: □2,288 Cr; Subsidiary has 2 years of losses.	Note 1.28(vii): Auditor KAM highlights impairment of PSRIPL as a risk; management uses aggressive growth assumptions to avoid write-downs.
13	RPT quantum and trend	Neutral — cash management; □1,640 Cr held in inter-corporate deposits with HDFC Ltd.	□	Inter-corporate deposits: □1,640 Cr (FY23) vs □1,940 Cr (FY22).	Note 10: While large, deposits are with a high-quality counterparty (HDFC), though they represent idle core-business cash.
14	Dividend paid vs FCF adequacy	Profit ↓ — liquidity strain; dividend of □246 Cr paid despite negative Free Cash Flow.	□	FCF: -□370 Cr; Dividends Paid: □246 Cr.	Cash Flow: Paying dividends from borrowings or existing cash rather than generated FCF indicates potential liquidity pressure.
15	Auditor KAM: Subsidy Recognition	Revenue ↑ — estimation risk; recognition of NBS subsidy based on management estimates before government notification.	□	Coromandel Revenue: □29,799 Cr.	Risk of revenue mismatch if government finalizations differ from accruals.
16	Auditor KAM: Inventory Verification	Profit ↑↓ — measurement risk; PSRIPL uses volume-to-weight conversions for sugar/ coal heaps.	□	PSRIPL Inventory.	Physical verification method is inherently less precise than weight-based tracking.
17	Investment Value Erosion	Profit ↓ — capital loss; write-down of TIFERT loan and APGPCL investment to Nil.	□	TIFERT loan write-down: □16.09 Cr to Nil.	Indicates a pattern of value erosion in long-term strategic investments.
18	Logistical Inefficiency	Profit ↓ — margin hit; new provision for demurrages of □97.63 Cr.	□	Provision for Demurrages: □97.63 Cr.	Suggests significant logistical inefficiencies or port delays impacting operational costs.

4. MANAGEMENT & GOVERNANCE

A. Auditor Report & Key Audit Matters * **Audit Opinion:** Unqualified. * **KAM - Subsidy Income Recognition:** Auditor focused on the estimation of Nutrient Based Subsidy (NBS) rates and "reasonable assurance" of meeting Direct Benefit Transfer (DBT) conditions for Coromandel International. * **KAM - Inventory Verification (PSRIPL):** Auditor flagged the subjectivity of volume-to-weight conversions for raw sugar and coal heaps at the PSRIPL subsidiary. * **KAM - Impairment of Assets (PSRIPL):** Auditor highlighted the risk of overvaluation of PPE at the loss-making PSRIPL subsidiary. Management used "value in use" projections to avoid impairment. * **Internal Controls:** The internal financial control (IFC) system was deemed adequate and effective. * **Auditor Change:** Price Waterhouse Chartered Accountants LLP was appointed in 2022 for a 5-year term.

B. Related Party Transactions | Party | Relationship | Nature | Amount (□Cr) | Concern | |-------|--------------|--------|----------------|---------| | ***HDFC Ltd*** | Financial Institution | Inter-corporate Deposits | 1,640.00 Cr | ***High liquidity concentration*** | | ***TIFERT*** | Associate | Share Pledge for Debt | 33.75 Lakh Shares |

Encumbrance of assets | | Director-related Cos | KMP Interest | Receivables | 0.11 Cr | Negligible | | ***PSRIPL*** | Subsidiary | Investment Impairment | 105.96 Cr | ***Value erosion*** |

- **RPT Verdict: Monitor** — While direct tunneling is not evident, the encumbrance of associate shares and the massive 1,640 Cr ICD balance (456% of CFO) suggest significant cash lock-up in non-core assets while the core business is cash-constrained.

C. Shareholding | Shareholder Category | Mar 2023 (%) | Mar 2022 (%) | |:---------------------|-------------:|-------------:| | **Promoters** | 44.52 | 44.65 | | **FIIs** | 10.19 | 8.87 | | **DIIs** | 4.34 | 4.45 | | **Public** | 40.95 | 42.03 | * **Pledged Shares:** 0.00% of promoter holding.

D. Board Composition + KMP Compensation * **Board Independence:** 50% (5 out of 10 directors are independent). * **Women Directors:** 2 (Ms. Meghna Apparao, Dr. Rca Godbole). * **KMP Compensation:** Chairman M.M. Venkatachalam received 0.20 Cr. **M.M. Venkatachalam (Chairman) is the uncle of Muthiah Murugappan (WTD & CEO).** Detailed remuneration for MD, CEO, and CFO was not provided in the consolidated snippet, preventing a full correlation analysis with the 32.88% EBITDA growth.

F. Capital Allocation & Capex | Action | FY Current (Cr) | FY Prior (Cr) | % of CFO | Signal | |-------|--------------|--------|----------------|---------| | **Dividends** | 246.00 Cr | 349.00 Cr | 68.52% | | | ***Capex*** | 839.00 Cr | 449.00 Cr | 233.70% | | | ***Net Debt Change*** | 359.00 Cr | -1,000.00 Cr | 100.00% | | | ***Working Capital Investment*** | 2,022.00 Cr | -217.00 Cr | 563.23% | |

- **CAPEX Analytical Notes:**
  - **CFO Coverage of Capex:** Ratio is 0.43; CFO is insufficient to self-fund capex, requiring external debt.
  - **Nature of Capex:** Primarily growth-oriented (Sankili and Haliyal distillery units).
  - **Deployment Efficiency: CWIP spiked 3.5x to 486.00 Cr**, signaling a heavy investment phase not yet contributing to cash flows.
  - **Takeaway:** Value-neutral Debt is being used to fund a bloated working capital cycle and aggressive capex.

H. Risks * **Regulatory/Cane Pricing (High):** Government-fixed FRP can squeeze margins if sugar prices don't track costs. * **Subsidy Realization (High):** Dependence on NBS/DBT payments causes massive CFO/PAT divergence. * **Asset Impairment (High):** Loss-making PSRIPL subsidiary risks a write-down of its 2,288 Cr PPE base. * **Forex Volatility (Medium):** PSRIPL uses USD as functional currency, creating translation volatility. * **Logistical Inefficiency (Medium):** 97.63 Cr provision for demurrages impacts margins directly.

5. SCORECARD & VERDICT

Part A: Scorecard

Dimension	Rating (1–5)	Delta	Key Evidence	One-line Rationale
Business Quality	4	→	49.8% Sales Growth; Ethanol mix 22%	Strong pivot to high-margin Bio-energy and FMCG.
Financial Health	2	↓	D/E 0.27x; CFO/PAT 0.20; FCF -□370 Cr	High growth but severe cash flow crunch and WC stress.
Earnings Quality	2	↓	CFO < PAT; 60-yr asset life; NBS estimates	Aggressive accounting and poor profit-to-cash conversion.
Management & Governance	3	→	50% Ind. Board; 0% Pledge; RPT ICDs	Compliant but high cash lock-up in non-core ICDs.
Capital Allocation & Earnings Visibility	3	↓	CWIP +3.5x; ROCE 27%; PSRIPL Impairment	Aggressive capex with high execution risk and subsidiary losses.

BUSINESS POSITIVES (for this company this year) * □**Revenue Growth:** Consolidated sales grew by **49.84%** to □35,244 Cr. * □**Strategic Pivot:** Ethanol now contributes **22%** of standalone revenue, reducing sugar cyclicality. * □**Capacity Expansion:** Distillery capacity is on track to reach **582 KLPD** by April 2024. * □**Operational Efficiency:** Sugar recovery in Karnataka reached a high of **11.89%**. * □**Debt Profile:** Overall Debt/Equity remains low at **0.27x** despite increased borrowings.

BUSINESS NEGATIVES / CONCERNS (for this company this year) * □**Cash Flow Divergence:** CFO (□**359 Cr**) is only **20%** of PAT (□**1,828 Cr**), a severe red flag. * □**Working Capital Stress:** Working capital changes drained □**2,022 Cr**, driven by a **39.4%** spike in finished goods inventory. * □**Subsidiary Performance:** PSRIPL refinery incurred a □**254 Cr** loss and a □**106 Cr** impairment. * □**Negative Free Cash Flow:** FCF turned negative at **-□370 Cr** due to aggressive capex and poor CFO. * □**Accounting Aggression:** Depreciation policy uses **60-year** lives for buildings, potentially overstating PAT.

OVERALL SCORECARD SUMMARY EID Parry is in a high-growth phase, successfully pivoting toward Bio-energy, but this is currently coming at the cost of financial health and earnings quality. While the balance sheet remains under-leveraged (D/E 0.27x), the massive disconnect between accounting profits and actual cash generation (CFO/PAT 0.20) indicates significant working capital and subsidy-related stress. Governance is stable with zero promoter pledging, but capital allocation is hampered by value erosion in the refinery subsidiary and large cash lock-ups in inter-corporate deposits. The business is on a **stable but high-risk trajectory**, where the success of the distillery expansion must urgently translate into cash flows to justify the current aggressive scaling.

Part B: Governance Check Matrix

#	Check	Status	Evidence
1	Audit opinion clean?	□	Unqualified opinion (p.96)
2	Promoter pledge = 0?	□	0.00% pledged
3	KMP pay < 5% of PAT?	□	Chairman pay □0.20 Cr vs □1,828 Cr PAT
4	RPT quantum < 5% of revenue?	□	Direct RPT receivables negligible (0.0003%)
5	Board > 50% independent?	□	50% (5/10)
6	At least 1 woman director?	□	2 Women Directors
7	No statutory dues outstanding?	□	No material defaults reported
8	No fraud reported?	□	None reported in AR
9	Audit trail enabled?	□	Confirmed in IFC report
10	Frequent Auditor change	□	5-year term started 2022
Total: 10/10 □— Governance Rating: 5			

Part C: Investor Verdict

THESIS: A high-growth agri-science play transitioning from cyclical sugar to stable bio-energy, currently masked by a severe but likely temporary working capital/subsidy cash crunch. **OVERALL STANCE: WATCH RATIONALE:** Strong business pivot and revenue growth are offset by poor earnings quality (CFO/PAT 0.20) and subsidiary losses. **RE-EVALUATE WHEN:** CFO/PAT ratio exceeds 0.70x for two consecutive quarters. **BULL CASE:** Ethanol capacity doubling leads to FCF generation of >□1,000 Cr and PSRIPL turnaround. **BEAR CASE:** Continued government subsidy delays and sugar price drops lead to a debt spiral to fund working capital. **KEY MONITORABLE:** Finished Goods Inventory: □3,007 Cr → Watch for reduction to <□2,200 Cr.

---

v5-Gemini | *126 pages* | *153 chunks*